568 related articles for article (PubMed ID: 26812490)
21. Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.
Thomas X; Pigneux A; Raffoux E; Huguet F; Caillot D; Fenaux P
Haematologica; 2006 Jul; 91(7):996-7. PubMed ID: 16757416
[TBL] [Abstract][Full Text] [Related]
22. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.
Song X; Hu X; Lü S; Gao L; Chen L; Yang J; Zhang W; Wang J
Eur J Haematol; 2014 Jul; 93(1):54-62. PubMed ID: 24592821
[TBL] [Abstract][Full Text] [Related]
23. Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran.
Alimoghaddam K; Ghavamzadeh A; Jahani M; Mousavi A; Iravani M; Rostami S; Ghaffari H; Hosseini R; Jalili M
Arch Iran Med; 2011 May; 14(3):167-9. PubMed ID: 21529103
[TBL] [Abstract][Full Text] [Related]
24. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
Che-Pin Lin ; Huang MJ; Chang IY; Lin WY; Sheu YT
Leuk Lymphoma; 2000 Jun; 38(1-2):195-8. PubMed ID: 10811463
[TBL] [Abstract][Full Text] [Related]
25. [Comparison of efficacy and adverse effects between arsenic trioxide and all-trans retinoic acid in patients with acute promyelocytic leukemia].
Jiao L; Wang SJ; Zhuang JL; Zhao YQ; Zhou DB; Xu Y; Han B; Zhang W; Duan MH; Zou N; Zhu TN; Shen T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):555-8. PubMed ID: 19968069
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes.
Efficace F; Mandelli F; Avvisati G; Cottone F; Ferrara F; Di Bona E; Specchia G; Breccia M; Levis A; Sica S; Finizio O; Kropp MG; Fioritoni G; Cerqui E; Vignetti M; Amadori S; Schlenk RF; Platzbecker U; Lo-Coco F
J Clin Oncol; 2014 Oct; 32(30):3406-12. PubMed ID: 25245446
[TBL] [Abstract][Full Text] [Related]
27. Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?
Tsimberidou AM; Kantarjian H; Keating MJ; Estey E
Leuk Lymphoma; 2006 Nov; 47(11):2282-8. PubMed ID: 17107899
[TBL] [Abstract][Full Text] [Related]
28. What is the standard regimen for patients with acute promyelocytic leukemia?
Lo-Coco F; Cicconi L
Curr Hematol Malig Rep; 2014 Jun; 9(2):138-43. PubMed ID: 24729066
[TBL] [Abstract][Full Text] [Related]
29. [Effects of all-trans retinoic acid and arsenic trioxide on tissue factor expression of acute promyelocytic leukemia cells].
Guo W; Wang H; Zhao W
Zhonghua Yi Xue Za Zhi; 2000 May; 80(5):327-31. PubMed ID: 11798779
[TBL] [Abstract][Full Text] [Related]
30. Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5-year prospective study.
Gill H; Kumana CR; Yim R; Hwang YY; Chan TSY; Yip SF; Lee HKK; Mak V; Lau JSM; Chan CC; Kho B; Wong RSM; Li W; Lin SY; Lau CK; Ip HW; Leung RYY; Lam CCK; Kwong YL
Cancer; 2019 Sep; 125(17):3001-3012. PubMed ID: 31090936
[TBL] [Abstract][Full Text] [Related]
31. The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia.
Wang F; Jia JS; Wang J; Zhao T; Jiang Q; Jiang H; Zhu HH
Leuk Res; 2017 Oct; 61():84-88. PubMed ID: 28934679
[TBL] [Abstract][Full Text] [Related]
32. Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction.
Li J; Zhu H; Hu J; Mi J; Chen S; Chen Z; Wang Z
Int J Hematol; 2014 Jul; 100(1):38-50. PubMed ID: 24938378
[TBL] [Abstract][Full Text] [Related]
33. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia.
Soignet SL
Oncologist; 2001; 6 Suppl 2():11-6. PubMed ID: 11331435
[TBL] [Abstract][Full Text] [Related]
34. Differentiation syndrome and coagulation disorder - comparison between treatment with oral and intravenous arsenics in pediatric acute promyelocytic leukemia.
Luo JS; Zhang XL; Huang DP; Chen YQ; Wan WQ; Mai HR; Chen HQ; Wen H; Liu RY; Chen GH; Li Y; Luo XQ; Tang YL; Huang LB
Ann Hematol; 2023 Jul; 102(7):1713-1721. PubMed ID: 37199788
[TBL] [Abstract][Full Text] [Related]
35. Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia. Keio Hematology-Oncology Cooperative Study Group (KHOCS).
Watanabe R; Murata M; Takayama N; Tokuhira M; Kizaki M; Okamoto S; Kawai Y; Watanabe K; Murakami H; Kikuchi M; Nakamura S; Ikeda Y
Thromb Haemost; 1997 Apr; 77(4):641-5. PubMed ID: 9134635
[TBL] [Abstract][Full Text] [Related]
36. Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
Sasaki M; Sugimoto K; Isobe Y; Oshimi K
Eur J Haematol; 2008 Aug; 81(2):160. PubMed ID: 18363868
[No Abstract] [Full Text] [Related]
37. Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide.
Shen Y; Fu YK; Zhu YM; Lou YJ; Gu ZH; Shi JY; Chen B; Chen C; Zhu HH; Hu J; Zhao WL; Mi JQ; Chen L; Zhu HM; Shen ZX; Jin J; Wang ZY; Li JM; Chen Z; Chen SJ
EBioMedicine; 2015 Jun; 2(6):563-71. PubMed ID: 26285909
[TBL] [Abstract][Full Text] [Related]
38. Successful treatment of all-trans retinoic acid resistant and chemotherapy naïve acute promyelocytic patients with arsenic trioxide--two case reports.
Lin CP; Huang MJ; Chang IY; Lin WY
Leuk Lymphoma; 2000 Jun; 38(1-2):191-4. PubMed ID: 10811462
[TBL] [Abstract][Full Text] [Related]
39. Arsenic trioxide and all-trans retinoic acid in the treatment of children with newly diagnosed acute promyelocytic leukemia.
Li SY; Lu Y; Liu HC; Gang EJ; Le J; Qian SY; Tang SH; Si T; Pei RZ
Leuk Lymphoma; 2021 May; 62(5):1267-1270. PubMed ID: 33439058
[No Abstract] [Full Text] [Related]
40. Acute promyelocytic leukemia: do we have a new front-line standard of treatment?
Sanz MA; Iacoboni G; Montesinos P
Curr Oncol Rep; 2013 Oct; 15(5):445-9. PubMed ID: 23990383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]